DaVita Expands Term Loan Facility, Enhancing Capital Flexibility
Introducing TipRanks MCP for Agents
- Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
- Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
DaVita ( (DVA) ) has issued an announcement.
On June 8, 2026, DaVita Inc. amended its existing credit agreement to add $500 million in incremental Tranche B-2 term loans maturing in May 2031, denominated in U.S. dollars and bearing interest at either a base rate or Term SOFR plus an applicable margin. DaVita is using or has used the proceeds to repay a portion of its senior secured revolving credit facility, cover related fees and expenses, and support general corporate purposes, adjusting its capital structure and liquidity profile.
On June 4, 2026, DaVita held its virtual 2026 annual meeting of stockholders, where approximately 91% of outstanding shares were represented, and shareholders elected nine directors for terms expiring at the 2027 meeting. Investors also ratified KPMG LLP as the independent auditor for 2026 and approved, on an advisory basis, the compensation of the company’s named executive officers, signaling broad shareholder support for current governance, oversight, and pay practices.
The most recent analyst rating on (DVA) stock is a Hold
with a $201.00 price target.
To see the full list of analyst forecasts on DaVita stock,
see the DVA Stock Forecast page.
Spark’s Take on DVA Stock
According to Spark, TipRanks’ AI Analyst, DVA is a Neutral.
The score is anchored by solid operating results and strong free cash flow, reinforced by a positive earnings update with raised 2026 guidance. The main constraint is elevated financial risk from high leverage and negative equity, while technicals show strong trend but very overbought conditions that raise short-term downside risk; valuation appears reasonable at ~13x earnings.
To see Spark’s full report on DVA stock,
click here.
More about DaVita
DaVita Inc. is a U.S.-based health care provider specializing in kidney care, primarily operating dialysis centers and related services for patients with chronic kidney disease and end-stage renal disease. The company serves a broad patient base through outpatient clinics and associated care programs, competing within the specialized renal care segment of the health care industry.
Average Trading Volume: 872,699
Technical Sentiment Signal: Buy
Current Market Cap: $12.34B
See more insights into DVA stock on TipRanks’ Stock Analysis page.
